HKSE - Delayed Quote HKD

Consun Pharmaceutical Group Limited (1681.HK)

5.580 +0.180 (+3.33%)
At close: 4:08 PM GMT+8

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Mr. Meng An CEO & Executive Chairman 18.13M -- 1972
Prof. Quan Zhu Chief Scientist & Executive Director 4.07M -- 1940
Mr. Hanxing Xu Assistant GM, Financial Manager & Executive Director 816.63k -- 1994
Mr. Peicheng Fang CFO & VP -- -- 1979
Lei Zhou Assistant President -- -- --
Mr. Haien Gao Board Secretary -- -- 1969
Mr. Chi Ming Yau CPA Company Secretary -- -- 1968
Mr. Guorong Guo Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd -- -- --
Ms. Lianhui Chen Chairman & GM of Consun Pharmaceutical(Inner Mongolia) Co. Ltd -- -- --

Consun Pharmaceutical Group Limited

71, Dongpeng Avenue
Eastern section Guangzhou Eco & Tech Dev Dist.
Guangzhou
China
86 20 8226 4529 https://www.chinaconsun.com
Sector: 
Healthcare
Full Time Employees: 
3,127

Description

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Corporate Governance

Consun Pharmaceutical Group Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Mar 28, 2024
Consun Pharmaceutical Group Limited Earnings Call

Jun 11, 2024

Ex-Dividend Date

Related Tickers